

SOUTHWESTERN NEWS

Media Contact: Staishy Bostick Siem
214-648-3404
staishy.siem@utsouthwestern.edu

Patients sought for depression, autism and aspirin resistance clinical trials

DALLAS – March 21, 2005 – Researchers at UT Southwestern Medical Center are seeking patients to participate in medical studies on exercise and depression, autism and aspirin resistance. All clinical trials are approved by UT Southwestern's Institutional Review Board, which reviews them for benefits, risks, side effects and informed consent.

Exercise and depression

People who continue to experience symptoms of depression while taking antidepressant medication could be eligible for a UT Southwestern Medical Center study investigating the added benefits of a supervised exercise program. Participants should be between the ages of 18 and 70 and be taking a selective serotonin re-uptake inhibitor (SSRI) – such as Zoloft, Prozac, Paxil, Celexa or Lexapro – but still feel depressed. Qualified individuals must be willing to participate in a 12-week exercise program, with regular sessions held at The Cooper Institute in North Dallas. For more information, call 214-648-0153.

Autism

If your child is 1 to 3 years old and has been diagnosed with autism, pervasive developmental disorder (PDD) or autism spectrum disorder (ASD), he or she may be eligible to help in a research study at UT Southwestern Medical Center. The study will include cutting a small sample of the child's hair for trace metal analysis, as well as taking part in an evaluation and two surveys. If interested, contact Dr. Janet Kern at 214-648-0159.

Aspirin resistance

Researchers at UT Southwestern Medical Center are looking for healthy volunteers to participate in a study evaluating the effectiveness of a new tool designed to quickly measure aspirin resistance. To be eligible, volunteers must avoid aspirin or medications containing aspirin for 10 days before starting the study. Participants will take a standard dose of aspirin for three days and have blood drawn at the beginning and end of the study. Financial compensation and study-related medication will be provided. For more information, call 214-648-0203.

###